NEW YORK, Nov. 9, 2017 /PRNewswire/ -- If you want a Stock Review on XRAY, ATRS, IART, or BAX then come over …
(The following statement was released by the rating agency) LONDON, December 11 (Fitch) Fitch Ratings has revised Atrium European Real Estate Limited's (Atrium) Outlook to Positive from Stable, while affirming the company's Long- …
Antares Pharma Inc. ATRS was a big mover last session, as the company saw its shares rise more than 10% on the day. Shares moved up after the company along with Teva Pharmaceutical Industries Ltd announced the launch of the generic …
The company also gets F’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ONDK stock. Hi-Crush Partners LP. The company also gets F’s in sales growth, operating margin …
The stock is very attractive as an M&A target ... records are suggestive of continued progress in the clinic in the …
ticker=INFI (NASDAQ:INFI) Antares Pharma Inc.'s (NASDAQ:ATRS) stock moved 5.33% lower Thursday, to close the day at $3.73. The stock recorded a trading volume of 6,280,425 shares, which was above its three months average volume …
Nasdaq6mon
In after-hours, the stock was up 45.36% to $37.30 ... The FDA has declined to approve Antares Pharma Inc.'s (ATRS) Xyosted, a drug-device combination product, for the treatment of adult men with low testosterone associated with a …
and they also are very bullish on a mega-cap technology stock and a small-cap biotech. All are rated Buy at Jefferies. This small-cap biotech may prove to be a big-time winner for aggressive accounts. Antares Pharma Inc. (NASDAQ: ATRS) …
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly ... https://investorplace.com/2014/12/3-medical-devices-stocks-to-buy-now-wwin-atrs-mdt-33/.